CHICAGO—Philips is showcasing a strengthened cath lab offering and its Live 3D transesophageal echocardiogram (TEE), and the start of its U.S. clinical trials to evaluate medical positioning technology at the American College of Cardiology (ACC) Scientific Sessions this week.
Philips said its StentBoost Subtract addresses the rising need for systems that help clinicians gain better views of the heart’s anatomy for stent placement. Since the Society for Cardiovascular Angiography and Interventions (SCAI) recommended careful deployment of drug-eluting stents in late 2006, interest in improved stent and lumen visualization has risen sharply. In response, Philips said it has created the new StentBoost Subtract to meet this need for high-volume cath labs, which useful in assessing full stent expansion and apposition.
Philips and MediGuide jointly reported the commencement of U.S. clinical trials to evaluate medical positioning technology in the cath lab. Under investigational device exemption, Columbia New York Presbyterian (NYP) Hospital is using the Philips Allura Xper Flat Detector cath lab (Allura Xper FD10) integrated with MediGuide's Medical Positioning System technology and gMPS-enabled Guided Measurement Catheter, according to the companies.
Philips and MediGuide of Haifa, Israel have been working together in the field of cardiac navigation since 2003. The trial is being conducted by Giora Weisz, MD, and Jeffrey W. Moses, MD, from Columbia NYP.
Also at this year’s ACC, Philips is showcasing Live 3D transesophageal echocardiogram (TEE) on the iE33 Echocardiography system, which provides structural heart information from real time 3D echo images for cardiologists and the cath lab. With Philips Live 3D TEE, the 3D heart is displayed in motion, in real time to provide more information for diagnostic and decision-making steps and serves as a communication tool.